Lyra Therapeutics (NASDAQ: LYRA) withdraws appeal, faces Nasdaq delisting

Rhea-AI Filing Summary

Lyra Therapeutics, Inc. reported that it has withdrawn its appeal of Nasdaq’s February 2, 2026 delisting determination. As a result, Nasdaq has confirmed that trading in the company’s common stock will be suspended at the open of trading on Tuesday, March 17, 2026.

Nasdaq has also indicated it will file a Form 25 Notification of Delisting with the SEC after its internal procedural periods are completed. The company’s shares are currently listed on The Nasdaq Capital Market under the symbol LYRA.

Positive

• None.

Negative

• Trading suspension and delisting: Lyra Therapeutics withdrew its appeal of Nasdaq’s delisting decision, and Nasdaq will suspend trading in the company’s common stock on March 17, 2026, followed by a Form 25 delisting filing with the SEC.

Insights

Equity markets and listing standards analyst

Lyra is moving forward with a Nasdaq delisting after withdrawing its appeal.

Lyra Therapeutics has chosen not to continue contesting Nasdaq’s earlier decision to delist its shares, withdrawing its appeal of the February 2, 2026 determination. This clears the way for trading suspension on March 17, 2026 on The Nasdaq Capital Market.

Once Nasdaq files Form 25 with the SEC after its internal procedures, the company’s common stock will be formally removed from listing. That typically pushes trading to over-the-counter venues, which can reduce liquidity and widen bid-ask spreads for shareholders.

The key near-term milestone is the trading suspension date of March 17, 2026, followed by the Form 25 filing. Subsequent company communications or future filings would be needed to understand any plans for alternative listings or broader capital markets strategy.

NASDAQ false 0001327273 0001327273 2026-03-13 2026-03-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 13, 2026

Lyra Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-39273		84-1700838
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
480 Arsenal Way
Watertown, Massachusetts				02472
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 617 393-4600

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		LYRA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On March 13, 2026, Lyra Therapeutics, Inc. (the “Company”) received a letter (the “Letter”) from the Nasdaq Hearings Advisor at The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has withdrawn its appeal of the delisting determination issued by Nasdaq’s Listings Qualifications Staff on February 2, 2026. The Letter further confirms that as a result of the withdrawal of the Company’s appeal, trading in the Company’s common stock will be suspended at the open of trading on Tuesday, March 17, 2026.

In connection with the suspension of trading, Nasdaq has indicated that it will file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission after all internal procedural periods have run.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						Lyra Therapeutics, Inc.
Date: March 16, 2026				By:		/s/ Jason Cavalier
						Jason Cavalier, Authorized Signatory

FAQ

What did Lyra Therapeutics (LYRA) disclose about its Nasdaq listing status?

Lyra Therapeutics disclosed that it withdrew its appeal of Nasdaq’s February 2, 2026 delisting determination. As a result, Nasdaq confirmed trading in the company’s common stock will be suspended and a Form 25 Notification of Delisting will be filed with the SEC.

When will Lyra Therapeutics (LYRA) Nasdaq trading be suspended?

Trading in Lyra Therapeutics’ common stock on Nasdaq will be suspended at the open of trading on Tuesday, March 17, 2026. This suspension follows the company’s withdrawal of its appeal of Nasdaq’s earlier delisting determination issued on February 2, 2026.

Why is Lyra Therapeutics (LYRA) being delisted from Nasdaq?

The company stated that Nasdaq’s Listings Qualifications Staff issued a delisting determination on February 2, 2026, and Lyra later withdrew its appeal. The filing describes the procedural outcome but does not detail the underlying reasons for Nasdaq’s delisting decision.

What is the significance of Nasdaq filing Form 25 for Lyra Therapeutics (LYRA)?

Nasdaq indicated it will file a Form 25 Notification of Delisting with the SEC after internal procedures conclude. Form 25 formally removes the company’s common stock from Nasdaq listing, typically shifting trading to other markets and marking a major change in listing status.

What stock exchange and symbol does Lyra Therapeutics (LYRA) currently use?

Lyra Therapeutics’ common stock, with a par value of $0.001 per share, is listed on The Nasdaq Capital Market under the symbol LYRA. The filing explains that trading on this market will be suspended on March 17, 2026, following the withdrawn appeal.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 16.8 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 10.6 KB